trending Market Intelligence /marketintelligence/en/news-insights/trending/udrx_ccwxy60mnqfa9nsew2 content esgSubNav
In This List

Eisai, Meiji Seika's Parkinson's treatment succeeds in phase 2/3 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Eisai, Meiji Seika's Parkinson's treatment succeeds in phase 2/3 study

Eisai Co. Ltd. and Meiji Seika Pharma Co. Ltd. said the phase 2/3 study of investigational drug ME2125 met its main goal in Japanese patients with Parkinson's.

Preliminary results from the clinical trial showed that ME2125, or safinamide mesylate, was better at managing the disease in patients experiencing so-called wearing-off periods when compared to placebo.

The patients were already taking levodopa, one of the main drugs used to treat the disease. However, as the disease progresses, levodopa's duration of effect decreases and Parkinson's symptoms return before the next dose, which is known as the wearing-off phenomenon.

In March 2017, Eisai secured marketing rights in Japan and Asia to Meiji Seika's safinamide.

Meiji will continue clinical trials of the drug and submit a marketing authorization application in Japan in 2018, while Eisai will conduct studies and seek regulatory approval in the rest of Asia.